$ADAP
Adaptimmune Therapeutics PLC

2020 Q1 Form 10-K Financial Statement

#000155837020001571 Filed on February 27, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 2018 Q4
Revenue $761.0K $1.122M $1.480M
YoY Change -98.11% -65.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.260M $43.39M $10.82M
YoY Change -21.33% -0.48% 22.68%
% of Gross Profit
Research & Development $21.26M $97.50M $22.77M
YoY Change -3.43% -0.78% -9.46%
% of Gross Profit
Depreciation & Amortization $1.711M $7.172M $2.100M
YoY Change -6.4% -0.22% 21.39%
% of Gross Profit
Operating Expenses $21.26M $97.50M $33.59M
YoY Change -3.43% -0.78% -1.12%
Operating Profit -$29.76M -$139.8M
YoY Change -11.92% 69.7%
Interest Expense $1.820M $2.790M $1.040M
YoY Change -71.29% 634.21% 35.06%
% of Operating Profit
Other Income/Expense, Net $937.0K $75.00K -$4.980M
YoY Change -82.74% -100.48% -432.0%
Pretax Income -$28.10M -$136.9M -$36.04M
YoY Change 2.51% 44.1% 31.39%
Income Tax $70.00K $242.0K $140.0K
% Of Pretax Income
Net Earnings -$28.17M -$137.2M -$36.17M
YoY Change 2.75% 43.61% 32.69%
Net Earnings / Revenue -3701.31% -12225.04% -2443.92%
Basic Earnings Per Share -$0.22
Diluted Earnings Per Share -$38.08K -$0.22 -$57.65K
COMMON SHARES
Basic Shares Outstanding 780.5M 629.8M
Diluted Shares Outstanding 629.8M

Balance Sheet

Concept 2020 Q1 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $196.4M $89.50M $205.1M
YoY Change 16.78% -56.36% -1.52%
Cash & Equivalents $86.43M $50.40M $68.38M
Short-Term Investments $110.0M $39.10M $136.8M
Other Short-Term Assets $908.0K $10.30M $439.0K
YoY Change -90.64% 32.05% -97.98%
Inventory
Prepaid Expenses $6.468M $6.279M
Receivables $0.00 $192.0K
Other Receivables $20.70M $18.00M
Total Short-Term Assets $227.8M $120.5M $231.1M
YoY Change 13.71% -47.86% 0.39%
LONG-TERM ASSETS
Property, Plant & Equipment $28.67M $51.90M $36.12M
YoY Change -52.37% 43.77% -11.26%
Goodwill
YoY Change
Intangibles $2.366M $1.473M
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.900M $7.000M $8.100M
YoY Change -17.86% -13.58% -8.99%
Total Long-Term Assets $57.48M $61.00M $45.64M
YoY Change -18.0% 33.77% -10.33%
TOTAL ASSETS
Total Short-Term Assets $227.8M $120.5M $231.1M
Total Long-Term Assets $57.48M $61.00M $45.64M
Total Assets $285.2M $181.5M $276.7M
YoY Change 5.49% -34.41% -1.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.066M $6.400M $4.083M
YoY Change 30.85% 56.1% -51.39%
Accrued Expenses $18.50M $25.80M $20.35M
YoY Change 4.53% 29.0% -24.05%
Deferred Revenue $1.658M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.82M $34.30M $24.44M
YoY Change 27.42% 40.57% -67.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $585.0K $23.60M $5.414M
YoY Change -97.86% 337.04% 42.47%
Total Long-Term Liabilities $585.0K $23.60M $5.414M
YoY Change -97.86% 337.04% 42.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.82M $34.30M $24.44M
Total Long-Term Liabilities $585.0K $23.60M $5.414M
Total Liabilities $99.20M $57.90M $29.85M
YoY Change 95.28% 93.65% -61.83%
SHAREHOLDERS EQUITY
Retained Earnings -$483.8M -$318.5M
YoY Change
Common Stock $1.139M $939.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $186.0M $123.6M $246.9M
YoY Change
Total Liabilities & Shareholders Equity $285.2M $181.5M $276.7M
YoY Change 5.49% -34.41% -1.55%

Cashflow Statement

Concept 2020 Q1 2019 2018 Q4
OPERATING ACTIVITIES
Net Income -$28.17M -$137.2M -$36.17M
YoY Change 2.75% 43.61% 32.69%
Depreciation, Depletion And Amortization $1.711M $7.172M $2.100M
YoY Change -6.4% -0.22% 21.39%
Cash From Operating Activities $16.86M -$112.5M -$31.69M
YoY Change -146.56% 7.78% 48.36%
INVESTING ACTIVITIES
Capital Expenditures $192.0K $1.592M -$220.0K
YoY Change -78.76% -59.28% -88.6%
Acquisitions
YoY Change
Other Investing Activities -$71.60M $98.02M -$52.19M
YoY Change -481.46% -868.78% 37.05%
Cash From Investing Activities -$71.95M $94.95M -$52.41M
YoY Change -507.49% -643.88% 30.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $90.55M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 91.44M 366.0K 100.0K
YoY Change 253911.11% -99.64%
NET CHANGE
Cash From Operating Activities 16.86M -112.5M -31.69M
Cash From Investing Activities -71.95M 94.95M -52.41M
Cash From Financing Activities 91.44M 366.0K 100.0K
Net Change In Cash 35.85M -17.57M -84.00M
YoY Change -298.23% 11.05% 36.87%
FREE CASH FLOW
Cash From Operating Activities $16.86M -$112.5M -$31.69M
Capital Expenditures $192.0K $1.592M -$220.0K
Free Cash Flow $16.67M -$114.1M -$31.47M
YoY Change -144.91% 5.36% 61.97%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
OX14 4RX
CY2019 dei Entity Address Country
EntityAddressCountry
GB
CY2019 dei City Area Code
CityAreaCode
44
CY2019 dei Local Phone Number
LocalPhoneNumber
1235 430000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
631003568
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001621227
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
627454270
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
001-37368
CY2019 dei Entity Registrant Name
EntityRegistrantName
ADAPTIMMUNE THERAPEUTICS PLC
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
60 Jubilee Avenue, Milton Park
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Abingdon, Oxfordshire
CY2019 dei Security12b Title
Security12bTitle
American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
CY2019 dei Trading Symbol
TradingSymbol
ADAP
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 dei Entity Public Float
EntityPublicFloat
348548767
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
780451790
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50412000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68379000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39130000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
136755000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
192000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30947000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25769000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
120489000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
231095000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5414000
CY2019Q4 us-gaap Liabilities
Liabilities
57905000
CY2018Q4 us-gaap Liabilities
Liabilities
29851000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4496000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4097000
CY2019Q4 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
2503000
CY2018Q4 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
3953000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20789000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31068000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36118000
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2198000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1473000
CY2019Q4 us-gaap Assets
Assets
181543000
CY2018Q4 us-gaap Assets
Assets
276736000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6357000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4083000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2493000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23363000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20354000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2128000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34341000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24437000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22966000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
598000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
785857300
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
631003568
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
701103126
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
627454270
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
943000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
939000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
585623000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
574208000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7264000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9763000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455664000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318499000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
246885000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181543000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
276736000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59505000
CY2019 adap Operating Losses Accrued On Firm Purchase Commitments
OperatingLossesAccruedOnFirmPurchaseCommitments
5000000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97501000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98269000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43391000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43601000
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
140892000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
141870000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-139770000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-82365000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2772000
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
2849000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
75000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15501000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136923000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-95017000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
497000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-95514000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
629805218
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
584338942
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-95514000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2018 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9478000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
8260000
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11783000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1145000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2018 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
13000
CY2018 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
-2473000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-134666000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83636000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
202984000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
8645000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest Adjusted Balance1
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1
211629000
CY2018 adap Stock Issued During Period Value Stock Options Issued Upon Completion Of Direct Registered Offering
StockIssuedDuringPeriodValueStockOptionsIssuedUponCompletionOfDirectRegisteredOffering
99653000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3037000
CY2018 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
8260000
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1145000
CY2018 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2018 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
-2473000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
366000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9478000
CY2018 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
0
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
11783000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-95514000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16202000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
246885000
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2019 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
0
CY2019 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-185000
CY2018 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
237000
CY2019 adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
1436000
CY2018 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2473000
CY2019 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1076000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-9747000
CY2018 adap Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
5162000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1450000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-742000
CY2019 adap Increase Decrease In Payables And Deferred Revenue
IncreaseDecreaseInPayablesAndDeferredRevenue
7603000
CY2018 adap Increase Decrease In Payables And Deferred Revenue
IncreaseDecreaseInPayablesAndDeferredRevenue
-40923000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112507000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-104388000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1592000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3910000
CY2019 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1482000
CY2018 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
798000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
125303000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
138038000
CY2019 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
13000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11053000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123638000
CY2019 us-gaap Profit Loss
ProfitLoss
-137165000
CY2018 us-gaap Profit Loss
ProfitLoss
-95514000
CY2019 us-gaap Depreciation
Depreciation
7172000
CY2018 us-gaap Depreciation
Depreciation
7188000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
838000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
622000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
11053000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
16202000
CY2019 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
13000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27284000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
150787000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
94945000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17457000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99653000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
366000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3037000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
102690000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-372000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3335000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17568000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15820000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72476000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88296000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72476000
CY2019 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3426000
CY2018 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
3114000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
201000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
258000
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to </span>people with cancer. We are a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”) against those targets, and produce therapeutic candidates (“SPEAR T-cells”) for administration to patients.</p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its SPEAR T-cells, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s SPEAR T-cells, the need to develop a reliable commercial manufacturing process, the need to commercialize any T-cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its SPEAR T-cell<span style="white-space:pre-wrap;">s, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$455.7 million as of December 31, 2019.</p>
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-455700000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b>          <b style="font-weight:bold;">Use of estimates in financial statements</b></p><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, valuation allowances relating to deferred tax assets, revenue recognition, assessment of the utility of clinical materials, estimation of the incremental borrowing rate for operating leases, estimating clinical trial expenses and estimating R&amp;D tax and expenditure credits. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p>
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50400000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
39100000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
123600000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137200000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-112500000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1100000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4097000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50412000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68379000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
4496000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54908000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
72476000
CY2019 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
125303000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
138038000
CY2019 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
13000
CY2018 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
2473000
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
0
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
3399000
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
4556000
CY2018 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
210000
CY2019 adap Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
18649000
CY2018 adap Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
17299000
CY2019 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1904000
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1847000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-137165000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-95514000
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-137165000
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-95514000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
629805218
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
584338942
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59505000
CY2017Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30090000
CY2019 adap Contract With Customer Liability Amounts Invoiced In Period
ContractWithCustomerLiabilityAmountsInvoicedInPeriod
3217000
CY2018 adap Contract With Customer Liability Amounts Invoiced In Period
ContractWithCustomerLiabilityAmountsInvoicedInPeriod
30077000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1122000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
59505000
CY2018 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
10396000
CY2018 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
5027000
CY2019 adap Contract With Customer Liability Foreign Exchange On Consolidation
ContractWithCustomerLiabilityForeignExchangeOnConsolidation
33000
CY2018 adap Contract With Customer Liability Foreign Exchange On Consolidation
ContractWithCustomerLiabilityForeignExchangeOnConsolidation
4707000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2128000
CY2019Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2100000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50412000
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
39130000
CY2019Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
4496000
CY2019 adap Concentration Risk Customers Number
ConcentrationRiskCustomersNumber
1
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
0
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
192000
CY2019Q4 adap Receivables Past Due Amount
ReceivablesPastDueAmount
0
CY2019Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
1.31
CY2019Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
19284000
CY2018Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
16459000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8395000
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
6279000
CY2019Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
1459000
CY2018Q4 adap Clinical Materials Current
ClinicalMaterialsCurrent
1087000
CY2019Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1387000
CY2018Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1505000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
422000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
439000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
30947000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25769000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54717000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52042000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23649000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15924000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
31068000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36118000
CY2019 us-gaap Depreciation
Depreciation
7172000
CY2018 us-gaap Depreciation
Depreciation
7188000
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
4299000
CY2018Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2691000
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2101000
CY2018Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1218000
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2198000
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1473000
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
838000
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
622000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
887000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
668000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
535000
CY2019Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
102000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
4017000
CY2019 us-gaap Short Term Lease Cost
ShortTermLeaseCost
319000
CY2019 us-gaap Lease Cost
LeaseCost
4336000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
4063000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.072
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4191000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4234000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4237000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4004000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3936000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
12748000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
33350000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7890000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
25460000
CY2019Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
8782000
CY2018Q4 adap Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
9637000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6863000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7553000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2662000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Four Years
OperatingLeasesFutureMinimumPaymentsReceivableInFourYears
3772000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Five Years
OperatingLeasesFutureMinimumPaymentsReceivableInFiveYears
3309000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable Thereafter
OperatingLeasesFutureMinimumPaymentsReceivableThereafter
13772000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable
OperatingLeasesFutureMinimumPaymentsReceivable
31958000
CY2019Q4 us-gaap Purchase Obligation
PurchaseObligation
5000000
CY2016Q2 adap Period Of Supply Contract Agreement
PeriodOfSupplyContractAgreement
P5Y
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2422000
CY2019Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
5000000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
56000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
742000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23363000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20354000
CY2019 adap Period Of Recorded Purchase Obligation
PeriodOfRecordedPurchaseObligation
P5Y
CY2019 adap Operating Losses Accrued On Firm Purchase Commitments
OperatingLossesAccruedOnFirmPurchaseCommitments
5000000.0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable Current
OperatingLeasesFutureMinimumPaymentsReceivableCurrent
3682000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Two Years
OperatingLeasesFutureMinimumPaymentsReceivableInTwoYears
3695000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Receivable In Three Years
OperatingLeasesFutureMinimumPaymentsReceivableInThreeYears
3728000
CY2019Q4 adap Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
1
CY2019Q4 adap Stockholders Equity Note Poll Votes Per Share
StockholdersEquityNotePollVotesPerShare
1
CY2017Q2 adap Stockholders Equity Note Authority Of Directors To Allot New Shares Or Grant Rights Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotNewSharesOrGrantRightsMaximumAggregateNominalAmount
207288.00
CY2017Q2 adap Period Of Authority To Directors To Allot Grant Rights And Covert Any Security
PeriodOfAuthorityToDirectorsToAllotGrantRightsAndCovertAnySecurity
P5Y
CY2017Q2 adap Stockholders Equity Note Authority Of Directors To Allot Shares Or Grant Rights Without First Offering To Existing Shareholders Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotSharesOrGrantRightsWithoutFirstOfferingToExistingShareholdersMaximumAggregateNominalAmount
157500.00
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Grants Maximum Value Per Participant
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumValuePerParticipant
30000
CY2019 adap Schedule Of Share Based Compensation Granted To Non Executive Directors
ScheduleOfShareBasedCompensationGrantedToNonExecutiveDirectors
<p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on May 11, 2015:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">Immediately on grant date</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to a non-executive director on June 23, 2016:</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:_077b2224_a118_4955_996e_4d456da6b863"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly installments over the following two years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on August 11, 2016:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:_64522096_2546_4249_967b_c2100b65de39"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date </p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on November 28, 2016:</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:_b2074984_d599_483a_ad2a_0501b3a4a0ba"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly installments over the following two years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on July 3, 2017</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:_b02e736b_1b72_43e9_8bde_2ccb1483bc84"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">Options granted to non-executive directors on June 22, 2018:</p></td><td style="background-color:auto;vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:auto;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">100% on the <span style="-sec-ix-hidden:_5253a1fb_b87c_4518_8b9d_bbc74a3d3315"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to a non-executive director on July 5, 2018:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">25% on the <span style="-sec-ix-hidden:_3b025695_647b_4927_8647_83c9f7a4d2f7"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span> anniversary of the grant date and 75% in monthly instalments over the following two years</p></td></tr><tr><td style="background-color:auto;vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted to non-executive directors on July 2, 2019:</p></td><td style="background-color:auto;vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="background-color:auto;vertical-align:top;width:48.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">100% on the first anniversary of the grant date</p></td></tr></table>
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Percentage Of Initial Fully Diluted Share Capital Immediately Following Initial Public Offering
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsPercentageOfInitialFullyDilutedShareCapitalImmediatelyFollowingInitialPublicOffering
0.08
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Scheme Limit Grants Automatic Annual Increase Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemeLimitGrantsAutomaticAnnualIncreasePercentage
0.04
CY2015Q1 adap Share Based Compensation Arrangement By Share Based Payment Award Options Schemes Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemesNumber
3
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
497000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
242000
CY2019 adap Schedule Of Share Based Compensation Stock Options Vesting Information
ScheduleOfShareBasedCompensationStockOptionsVestingInformation
<p style="font-family:'Times New Roman';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.19;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;margin-left:-0.010307312%;padding-left:0pt;padding-right:0pt;width:100.02%;"><tr><td style="vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1pt;margin:0pt;"><span style="font-size:1pt;line-height:1.19;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:56.18%;margin:0pt;padding:0pt;"/></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted in 2009:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;">    </p></td><td style="background-color:#cceeff;vertical-align:top;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:15pt;margin-top:15pt;visibility:hidden;">​</span></p></td><td colspan="2" style="background-color:#cceeff;vertical-align:top;width:59.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">100%</span><span style="font-size:10pt;"> on the </span><span style="-sec-ix-hidden:_6d9371fc_b93d_455c_be8e_1efdf5948f41"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">third</span></span><span style="font-size:10pt;"> anniversary of the grant date</span></p></td></tr><tr><td style="vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted in 2011, 2012, 2013 and April 2014:</p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:top;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:15pt;margin-top:15pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">25%</span><span style="font-size:10pt;"> on the </span><span style="-sec-ix-hidden:_bf12c65d_68dc_4338_9f8e_afb8856c17ea"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span><span style="font-size:10pt;"> anniversary of the grant date and </span><span style="font-size:10pt;">75%</span><span style="font-size:10pt;"> in annual installments over the following </span><span style="font-size:10pt;">three years</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:25.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Options granted in December 2014:</p></td><td style="background-color:#cceeff;vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:top;width:13.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;margin-bottom:15pt;margin-top:15pt;visibility:hidden;">​</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman';font-size:12pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;">25%</span><span style="font-size:10pt;"> on the </span><span style="-sec-ix-hidden:_f42394aa_08f8_4d84_bcf8_e9eb4b08fe4b"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">first</span></span><span style="font-size:10pt;"> anniversary of the grant date and </span><span style="font-size:10pt;">75%</span><span style="font-size:10pt;"> in monthly installments over the following </span><span style="font-size:10pt;">three years</span></p></td></tr></table><p style="font-family:'Times New Roman';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11053000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16202000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10030000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2019 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3549298
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5334936
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1977000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6727000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
366000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3037000
CY2019 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
1488000
CY2018 us-gaap Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
1325000
CY2019 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.69
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.73
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.66
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.69
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0022
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0090
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
497000
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1251000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1415000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
2364000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
79000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136923000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-95017000
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
242000
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
400000
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
97000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
242000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3694000
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1415000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
9941000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
8020000
CY2019Q4 adap Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
1413000
CY2018Q4 adap Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
575000
CY2019Q4 adap Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
2550000
CY2019Q4 adap Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
48837000
CY2018Q4 adap Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
33310000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
125000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
286000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
62866000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
42191000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59172000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40776000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3694000
CY2018 adap Concentration Risk Customers Number
ConcentrationRiskCustomersNumber
1
CY2019 adap Concentration Risk Customers Number
ConcentrationRiskCustomersNumber
1
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1415000
CY2018 adap Valuation Allowance Deferred Tax Asset Increase Decrease Due To Adoption Of New Accounting Pronouncement
ValuationAllowanceDeferredTaxAssetIncreaseDecreaseDueToAdoptionOfNewAccountingPronouncement
-1469000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16961000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16659000
CY2019 adap Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
1435000
CY2018 adap Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
-1847000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
59172000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40776000
CY2019 adap Operating Loss Carryforwards And Tax Credit Carryforward Annual Allowance
OperatingLossCarryforwardsAndTaxCreditCarryforwardAnnualAllowance
5000000
CY2019Q4 adap Operating Loss Carryforwards And Tax Credit Carryforward Percentage On Taxable Profit
OperatingLossCarryforwardsAndTaxCreditCarryforwardPercentageOnTaxableProfit
0.50
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2019Q4 us-gaap Noncurrent Assets
NoncurrentAssets
51857000
CY2018Q4 us-gaap Noncurrent Assets
NoncurrentAssets
36118000
CY2019Q4 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
2503000
CY2018Q4 adap Clinical Materials Noncurrent
ClinicalMaterialsNoncurrent
3953000

Files In Submission

Name View Source Status
0001558370-20-001571-index-headers.html Edgar Link pending
0001558370-20-001571-index.html Edgar Link pending
0001558370-20-001571.txt Edgar Link pending
0001558370-20-001571-xbrl.zip Edgar Link pending
adap-20191231.xsd Edgar Link pending
adap-20191231x10kb99908.htm Edgar Link pending
adap-20191231x10kb99908001.jpg Edgar Link pending
adap-20191231x10kb99908_htm.xml Edgar Link completed
adap-20191231_cal.xml Edgar Link unprocessable
adap-20191231_def.xml Edgar Link unprocessable
adap-20191231_lab.xml Edgar Link unprocessable
adap-20191231_pre.xml Edgar Link unprocessable
ex-10d4.htm Edgar Link pending
ex-10d5.htm Edgar Link pending
ex-10d6.htm Edgar Link pending
ex-23d1.htm Edgar Link pending
ex-31d1.htm Edgar Link pending
ex-31d2.htm Edgar Link pending
ex-32d1.htm Edgar Link pending
ex-32d2.htm Edgar Link pending
ex-4d4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
R92.htm Edgar Link pending
R93.htm Edgar Link pending
R94.htm Edgar Link pending
R95.htm Edgar Link pending
R96.htm Edgar Link pending
R97.htm Edgar Link pending
R98.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending